Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Impact of Rapid Latex Immunoassay (LIA) Implementation on Management of Heparin Induced Thrombocytopenia (HIT): A Retrospective Single Institution Study

Julia Levy, Rabeka Ali, Mandy VanSandt, Shelby Koppinger, Francisco Hernandez-Ilizaliturri, Merav Sendowski

Blood (2024) 144 (Supplement 1): 3642.

https://doi.org/10.1182/blood-2024-212118

Published: 2024

Journal Articles

Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function

Taylor K Mandeville, Jacob P Wright, Cory Mavis, Matthew J. Cortese, MD, MPH, Spencer Rosario, Scott Olejniczak, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2024-212101

Published: 2024

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Maria Lia Palomba, Paolo F. Caimi, Matthew Mei, Francisco Hernandez-Ilizaliturri, Geoffrey Shouse, Allison M. Winter, Greg Yedinak, David Mou, Nestor Huang, Anna Moua, Martin Oft, Paul-Joseph Aspuria, Anita Mehta-Damani, Naiyer Rizvi, Sherry Unabia, Peg Taylor, Jeffrey McLeroy, Matthew J Cortese

Blood (2024) 144 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2024-202090

Published: 2024

Journal Articles

Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment

Matthew J. Cortese, MD, MPH, Jacob P Wright, Cory Mavis, Taylor K Mandeville, Alex Niu, Dae-Kyum Kim, Spencer Rosario, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 78.

https://doi.org/10.1182/blood-2024-212019

Published: 2024

Journal Articles

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Blood (2024) 144 (Supplement 1): 861.

https://doi.org/10.1182/blood-2024-200277

Published: 2024

Journal Articles

Evasion of αCD19 CAR T-Mediated Killing By Rituximab-Chemotherapy Resistant Lymphoma Cells

Taylor K Mandeville, Jacob P Wright, Cory Mavis, Matthew J. Cortese, MD, MPH, Spencer Rosario, Scott Olejniczak, Francisco Hernandez-Ilizaliturri

Blood (2024) 144 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2024-212215

Published: 2024

Journal Articles

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2024-199278

Published: 2024

Journal Articles

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2024-210053

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents

Shipra Goel, Brahm Segal, Elizabeth A. Griffiths, Francisco Hernandez-Ilizaliturri, Pallawi Torka, Matthew J Cortese, Paola Ghione, Michael J. Nemeth, Jason Muhitch

Blood (2022) 140 (Supplement 1): 6468–6469.

https://doi.org/10.1182/blood-2022-170369

Published: 2022

Journal Articles

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

Cory Mavis, Kevin Zablonski, Suchitra Sundaram, Juan Gu, Pallawi Torka, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 12357–12358.

https://doi.org/10.1182/blood-2022-169123

Published: 2022

Journal Articles

CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Klaudyna Fidyt, Marta Krawczyk, Monika Pepek, Katsiaryna Marhelava, Agnieszka Kraft, Malgorzata Bobrowicz, Aleksandra Kusowska, Joanna Barankiewicz, Przemyslaw Juszczynski, Michal Smida, Myron Czuczman, Francisco Hernandez-Ilizaliturri, Malgorzata Firczuk, Magdalena Winiarska

Blood (2022) 140 (Supplement 1): 10273–10274.

https://doi.org/10.1182/blood-2022-162292

Published: 2022

Journal Articles

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Taylor Mandeville, Cory Mavis, Juan Gu, Noah Lemoine, Kevin Bowman, Scott Olejniczak, Prasenjit Dey, Gyorgy Paragh, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 7398–7399.

https://doi.org/10.1182/blood-2022-170436

Published: 2022

Journal Articles

Iron Deficiency Is Commonly Observed in Female Multiple Sclerosis (MS) Patients with Relapsed/Refractory or Primary Progressive Disease Referred for Biological Therapies

Sarah Patel, Rajat Thawani, Thomas G. Deloughery, Vijayshree Yadav, Francisco Hernandez-Ilizaliturri, Merav Sendowski

Blood (2022) 140 (Supplement 1): 11086–11087.

https://doi.org/10.1182/blood-2022-170573

Published: 2022

Journal Articles

The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Othman Salim Akhtar, Andrea Anampa-Guzman, Matthew J Cortese, Alankrita Taneja, Sheeba Ba Aqeel, Paola Ghione, Francisco Hernandez-Ilizaliturri, Pallawi Torka

Blood (2022) 140 (Supplement 1): 5160–5161.

https://doi.org/10.1182/blood-2022-167826

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Manali Kamdar

Blood (2022) 140 (Supplement 1): 1581–1583.

https://doi.org/10.1182/blood-2022-159702

Published: 2022

Journal Articles

Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma

Kevin Bowman, Cory Mavis, Taylor K Mandeville, Noah Lemoine, Juan Gu, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 8850.

https://doi.org/10.1182/blood-2022-169438

Published: 2022

NARROW

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Impact of Rapid Latex Immunoassay (LIA) Implementation on Management of Heparin Induced Thrombocytopenia (HIT): A Retrospective Single Institution Study

Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Evasion of αCD19 CAR T-Mediated Killing By Rituximab-Chemotherapy Resistant Lymphoma Cells

Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents

PLX51107 Enhances the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia When Combined with Venetoclax

CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax

Iron Deficiency Is Commonly Observed in Female Multiple Sclerosis (MS) Patients with Relapsed/Refractory or Primary Progressive Disease Referred for Biological Therapies

The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)

Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only